Mercer Global Advisors
LAB icon

Mercer Global Advisors’s Standard BioTools LAB Stock Holding History

Mercer Global Advisors’s Portfolio LAB Stock Details LAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$83.4K Buy
101,381
+38,604
+61% +$36.5K ﹤0.01% 3459
2026
Q1 		$57.7K Buy
62,777
+11,790
+23% +$14.3K ﹤0.01% 3111
2025
Q4 		$65.3K Buy
+50,987
New +$68.5K ﹤0.01% 2768
2021
Q2 		– Sell
-25,000
Closed -$113K – 1706
2021
Q1 		$113K Buy
+25,000
New +$137K ﹤0.01% 1547

Other funds holding LAB

Casdin Capital
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
MAK Capital One
MAK Capital One New York $714M AUM 68.07% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.91B AUM 12.68% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HBWM
Hollow Brook Wealth Management Katonah, New York $504M AUM 26.89% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
Royce & Associates
Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return

Mercer Global Advisors's LAB Position: Q2 2026 in Review

Mercer Global Advisors increased its Standard BioTools (LAB) stake by 61% in Q2 2026, buying an estimated $36.5K and bringing the position to 101,381 shares worth $83.4K. The position accounts for ﹤0.01% of the portfolio, ranked #3459.

Mercer Global Advisors first reported a position in LAB in Q1 2021 and has held it in 4 quarters since. The position peaked at $113K in Q1 2021. 143 funds tracked by Wall St. Rank hold LAB as of Q2 2026.

  • Mercer Global Advisors held 101,381 shares of Standard BioTools worth $83.4K as of Q2 2026.
  • Mercer Global Advisors bought 38,604 Standard BioTools shares in Q2 2026, an estimated $36.5K.
  • Standard BioTools made up ﹤0.01% of Mercer Global Advisors's portfolio in Q2 2026, its #3459 holding.
  • Mercer Global Advisors first reported a position in Standard BioTools in Q1 2021 and has held it in 4 quarters since.
  • Mercer Global Advisors's Standard BioTools position peaked at $113K in Q1 2021.
  • 143 funds tracked by Wall St. Rank held Standard BioTools as of Q2 2026.

Based on Mercer Global Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.